AU4967193A - Use of macrolide compounds for the treatment of reversible obstructive airways disease - Google Patents

Use of macrolide compounds for the treatment of reversible obstructive airways disease

Info

Publication number
AU4967193A
AU4967193A AU49671/93A AU4967193A AU4967193A AU 4967193 A AU4967193 A AU 4967193A AU 49671/93 A AU49671/93 A AU 49671/93A AU 4967193 A AU4967193 A AU 4967193A AU 4967193 A AU4967193 A AU 4967193A
Authority
AU
Australia
Prior art keywords
treatment
obstructive airways
airways disease
macrolide compounds
reversible obstructive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU49671/93A
Other languages
English (en)
Inventor
Catherine Hallam
Stephen Thomas Harper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fisons Ltd
Original Assignee
Fisons Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fisons Ltd filed Critical Fisons Ltd
Publication of AU4967193A publication Critical patent/AU4967193A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU49671/93A 1992-08-25 1993-08-20 Use of macrolide compounds for the treatment of reversible obstructive airways disease Abandoned AU4967193A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9218027 1992-08-25
GB929218027A GB9218027D0 (en) 1992-08-25 1992-08-25 Novel method of treatment
PCT/GB1993/001769 WO1994004148A1 (en) 1992-08-25 1993-08-20 Use of macrolide compounds for the treatment of reversible obstructive airways disease

Publications (1)

Publication Number Publication Date
AU4967193A true AU4967193A (en) 1994-03-15

Family

ID=10720906

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49671/93A Abandoned AU4967193A (en) 1992-08-25 1993-08-20 Use of macrolide compounds for the treatment of reversible obstructive airways disease

Country Status (6)

Country Link
AU (1) AU4967193A (xx)
GB (1) GB9218027D0 (xx)
IL (1) IL106751A0 (xx)
MX (1) MX9305152A (xx)
WO (1) WO1994004148A1 (xx)
ZA (1) ZA936137B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP223198A0 (en) * 1998-03-06 1998-04-02 Fujisawa Pharmaceutical Co., Ltd. New use
GB9917158D0 (en) * 1999-07-21 1999-09-22 Fujisawa Pharmaceutical Co New use
TWI310688B (en) 1999-10-29 2009-06-11 Nektar Therapeutics Dry powder compositions having improved dispersivity
US6878751B1 (en) * 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
AR035411A1 (es) * 2000-12-29 2004-05-26 Fujisawa Pharmaceutical Co Uso de un derivado de tacrolimus para fabricar un agente neurotrofico, composiciones y articulos de fabricacion o kits que lo comprenden, metodo para fabricar un agente que lo comprende y tejidos e injertos con una celula nerviosa tratada con este compuesto
WO2005067928A1 (en) * 2004-01-20 2005-07-28 Astellas Pharma Inc. Method for treating erectile dysfunction
EP3538531A1 (en) 2016-11-10 2019-09-18 Novartis AG Bmp potentiators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0346427B1 (en) * 1987-12-09 1995-03-29 FISONS plc Macrocyclic compounds
IE64214B1 (en) * 1989-06-06 1995-07-26 Fujisawa Pharmaceutical Co Macrolides for the treatment of reversible obstructive airways diseases
GR1001225B (el) * 1989-09-14 1993-06-30 Fisons Plc Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους.
IE65341B1 (en) * 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds

Also Published As

Publication number Publication date
IL106751A0 (en) 1993-12-08
GB9218027D0 (en) 1992-10-14
MX9305152A (es) 1994-05-31
WO1994004148A1 (en) 1994-03-03
ZA936137B (en) 1994-02-21

Similar Documents

Publication Publication Date Title
AU5016593A (en) Apparatus for the diagnosis of sleep apnea
AU2845492A (en) Dipyridamole for the treatment of proliferative diseases
AU4738496A (en) External fixator for distal radius fractures
AU1532492A (en) Use of heterocyclic compounds for the treatment of inflammatory pain
AU4048295A (en) Peptide medicaments for the treatment of disease
AU3938493A (en) Percutaneous surgical endoscopy
AU1197992A (en) The use of loperamide and related compounds for treatment of respiratory disease symptoms
HU9502520D0 (en) Pharmaceutical use of substituted 4-phenyl-6-amino-nicotinic acid derivatives
AU3628395A (en) Benz{g}indazolyl derivatives for the treatment of inflaminflammation
AU4967193A (en) Use of macrolide compounds for the treatment of reversible obstructive airways disease
AU9173191A (en) Medicaments for the treatment of papillomavirus diseases
AU2806692A (en) Medicament for the treatment of anxiety
IL115320A0 (en) Retinoyloxy (substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases
AU1530195A (en) Halogenated derivatives of 2,3'-(o)-cyclocytidine compounds and process for production thereof
AU3684395A (en) Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases
AU3574793A (en) Remedy for airway diseases
AU4476089A (en) Use of azepinone derivatives for the treatment of respiratory tract disorders
AU7503194A (en) Sodium cromoglycate for the treatment of upper respiratory tract infections
AU4081393A (en) Medicaments for the treatment of anxiety
AU8185491A (en) Treatment of disease
AU1807592A (en) New combination preparation for treatment of parkinson's disease
EP0755262A4 (en) PNEUMOPATHY TREATMENT COMPOSITION
AU7750794A (en) Use of hydroxychloroquine for treatment of graft-versus-host disease
AU697487B2 (en) Therapeutic agent for ischemic diseases
AU4728893A (en) Use of macrolide compounds for the treatment of skin diseases